These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
95 related articles for article (PubMed ID: 23667128)
1. Drug companies agree to cut price of HPV vaccine to developing countries to increase accessibility. Gulland A BMJ; 2013 May; 346():f3025. PubMed ID: 23667128 [No Abstract] [Full Text] [Related]
2. Latin America. Price is the main barrier to wider use of papillomavirus vaccine. Kaiser J Science; 2008 May; 320(5878):860. PubMed ID: 18487164 [No Abstract] [Full Text] [Related]
3. Market-based licensing for HPV vaccines in developing countries. Outterson K; Kesselheim AS Health Aff (Millwood); 2008; 27(1):130-9. PubMed ID: 18180488 [TBL] [Abstract][Full Text] [Related]
4. Introducing HPV vaccine in developing countries--key challenges and issues. Agosti JM; Goldie SJ N Engl J Med; 2007 May; 356(19):1908-10. PubMed ID: 17494923 [No Abstract] [Full Text] [Related]
5. Who should get the HPV vaccine? Usage expands amid debate. Peres J J Natl Cancer Inst; 2010 Jun; 102(12):838-40. PubMed ID: 20530765 [No Abstract] [Full Text] [Related]
6. HPV vaccine for MSM. Bush M Aust Nurs J; 2008 Sep; 16(3):33. PubMed ID: 18841719 [No Abstract] [Full Text] [Related]
7. GAVI injects new life into HPV vaccine rollout. Lancet; 2013 May; 381(9879):1688. PubMed ID: 23683613 [No Abstract] [Full Text] [Related]
8. Chapter 15: HPV vaccine use in the developing world. Kane MA; Sherris J; Coursaget P; Aguado T; Cutts F Vaccine; 2006 Aug; 24 Suppl 3():S3/132-9. PubMed ID: 16950000 [TBL] [Abstract][Full Text] [Related]
10. Lessons from the failure of human papillomavirus vaccine state requirements. Schwartz JL; Caplan AL; Faden RR; Sugarman J Clin Pharmacol Ther; 2007 Dec; 82(6):760-3. PubMed ID: 17971822 [TBL] [Abstract][Full Text] [Related]
11. Health and economic outcomes of HPV 16,18 vaccination in 72 GAVI-eligible countries. Goldie SJ; O'Shea M; Campos NG; Diaz M; Sweet S; Kim SY Vaccine; 2008 Jul; 26(32):4080-93. PubMed ID: 18550229 [TBL] [Abstract][Full Text] [Related]
12. Increased production and comprehensive guidelines needed for HPV vaccine. Phumaphi J; Gautam KC; Mason E; Lancet; 2020 Feb; 395(10221):319-321. PubMed ID: 32007151 [No Abstract] [Full Text] [Related]
13. Chapter 26: Innovative financing mechanisms to accelerate the introduction of HPV vaccines in developing countries. Batson A; Meheus F; Brooke S Vaccine; 2006 Aug; 24 Suppl 3():S3/219-25. PubMed ID: 16950010 [TBL] [Abstract][Full Text] [Related]
14. Mothers' preferences and willingness to pay for HPV vaccines in Vinh Long Province, Vietnam. Poulos C; Yang JC; Levin C; Van Minh H; Giang KB; Nguyen D Soc Sci Med; 2011 Jul; 73(2):226-34. PubMed ID: 21733609 [TBL] [Abstract][Full Text] [Related]
15. Merck, Bristol-Myers Squibb announce major price reductions for poorest countries: major access progress but questions remain. James JS AIDS Treat News; 2001 Feb; (361):5-7. PubMed ID: 12765151 [TBL] [Abstract][Full Text] [Related]
16. The case for vaccinating boys against human papillomavirus. Hull SC; Caplan AL Public Health Genomics; 2009; 12(5-6):362-7. PubMed ID: 19684448 [TBL] [Abstract][Full Text] [Related]
17. Vaccines for human papillomavirus infection: a critical analysis. Nath AK; Thappa DM Indian J Dermatol Venereol Leprol; 2009; 75(3):245-53; quiz 254. PubMed ID: 19439876 [TBL] [Abstract][Full Text] [Related]
18. The new vaccine to prevent HPV. Lajiness MJ Urol Nurs; 2007 Apr; 27(2):153-4. PubMed ID: 17494457 [No Abstract] [Full Text] [Related]
19. Cost-effectiveness analysis of human papillomavirus vaccination in the Netherlands. de Kok IM; van Ballegooijen M; Habbema JD J Natl Cancer Inst; 2009 Aug; 101(15):1083-92. PubMed ID: 19571256 [TBL] [Abstract][Full Text] [Related]
20. Physicians' experiences with HPV vaccine delivery: evidence from developing country with multiethnic populations. Wong LP Vaccine; 2009 Mar; 27(10):1622-7. PubMed ID: 19100803 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]